Voluntary Scheme - dispute resolution

When issues arise under the Voluntary Scheme for branded medicines pricing, access and growth, the Department of Health and Social Care (DHSC) and scheme participants will usually try to resolve them through early and informal discussion.

However, if significant issues arise that cannot be resolved by discussion, they can be referred to a formal dispute resolution process overseen by the VPAG dispute resolution panel.

The operation of this process is described in full in the 2024 VPAG scheme documents.

When the VPAG dispute resolution panel has formally considered a matter and made a decision, they will be highlighted on this page and published in full online by the government:

VPAG dispute resolution panel decisions:

• Dispute resolution panel, June 2025: DHSC and Haleon UK Ltd
• Dispute resolution panel decision February 2025: DHSC and B. Braun Medical Ltd 

Details
The VPAG dispute resolution panel operates under the 2024 voluntary scheme for branded medicines pricing, access and growth, to consider and provide reasoned decisions for disputes under the 2024, 2019, 2014, 2009, 2008 and 2005 schemes.

This page will be updated to include all dispute decisions.
Pharmaceutical Price Regulation Scheme (PPRS) dispute resolution panel decisions for 2012 to 2016 are available in a separate publication.